Molecular docking studies of novel s-triazine derivatives incorporating amino methoxy chalcone for EGFR inhibitor in breast cancer
DOI:
https://doi.org/10.46542/pe.2024.242.172178Keywords:
Amino-methoxy chalcone, Breast cancer, Docking, EGFR inhibitor, S-triazine derivativeAbstract
Background: The Epidermal growth factor receptor (EGFR) receptor is involved in both apoptosis and angiogenesis. An upregulation of EGFR activity can potentially expedite the proliferation of malignant cells. Anticancer activity is among the many pharmacological activities of s-triazine derivative compounds. The potential of amino chalcone derivatives as anticancer agents has been documented. The anticipated outcome is that the derivatives of these two compounds will enhance their efficacy as antiproliferative agents.
Objective: Through molecular docking, this study aimed to assess the potential of eight novel trichlorotriazin compounds derived from amino chalcone as EGFR inhibitors in breast cancer.
Method: The molecular docking process was carried out with the assistance of the software package identified as the molecular docking environment (MOE) 2023.0901.
Results: Compounds two and four, which have a similar binding orientation to the positive control, have the potential to inhibit EGFR, according to molecular docking results. For developing new s-triazine derivatives that are potent agents against breast cancer, the molecular docking outcomes of compounds two and four may require additional consideration.
Conclusion: Compounds which are two and four have surfaced as noteworthy contenders.
References
Alhameed, R., Almarhoon, Z., N. Sholkamy, E., Ali Khan, S., Ul-Haq, Z., Sharma, A., ... & El-Faham, A. (2020). Novel 4, 6-disubstituted s-triazin-2-yl amino acid derivatives as promising antifungal agents. Journal of Fungi, 6(4), 237. https://doi.org/10.3390/jof6040237
Anwar, C., Prasetyo, Y. D., Matsjeh, S., Haryadi, W., Sholikhah, E. N., & Nendrowati, N. (2018). Synthesis of chalcone derivatives and their in vitro anticancer test against breast (T47D) and colon (WiDr) cancer cell line. Indonesian Journal of Chemistry, 18(1), 102‒107. https://doi.org/10.22146/ijc.26864
Asadi, P., Alvani, M., Hajhashemi, V., Rostami, M., & Khodarahmi, G. (2021). “Design, synthesis, biological evaluation, and molecular docking study on triazine based derivatives as anti-inflammatory agents”. Journal of Molecular Structure, 1243(2021), 130760. https://doi.org/10.1016/j.molstruc.2021.130760
Barakat, A., El-Senduny, F. F., Almarhoon, Z., Al-Rasheed, H. H., Badria, F. A., Al-Majid, A. M., ... & El-Faham, A. (2019). Synthesis, X-ray crystal structures, and preliminary antiproliferative activities of new s-triazine-hydroxybenzylidene hydrazone derivatives. Journal of Chemistry, 2019. https://doi.org/10.1155/2019/9403908
Bray, F., Laversanne, M., Weiderpass, E., & Soerjomataram, I. (2021). The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 127(16), 302‒3030. https://doi.org/10.1002/cncr.33587
El-Faham, A., Farooq, M., Almarhoon, A., Alhameed, R.A., Wadaan, M.A.M., de la Torre, G., & Albericio, F. (2020). Di-and tri-substituted s-triazine derivatives: Synthesis, characterization, anticancer activity in human breast cancer cell lines, and developmental toxicity in zebrafish embryos. Bioorganic chemistry. https://doi.org/10.1016/j.bioorg.2019.103397
Frimayanti, N., Marzieh, Y., Ihsan, I., Dhea, R.W.P., Hamid, N., & Fatemeh, S.B. (2021). Insight on the in silico study and biological activity assay of chalcone-based 1, 5-benzothiazepines as potential inhibitor for breast cancer MCF7. CMUJ, 20(1), e2021019.
Giordano, S., & Petrelli, A. (2008). From single-to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. Current medicinal chemistry, 15(5), 422‒432. https://doi.org/10.2174/092986708783503212v
Hashem, H.E., E.Amr, A.E., Nossier, E.S., Anwar, M.M., & Azmy, E.M. (2022). New Benzimidazole‑, 1,2,4-Triazole‑, and 1,3,5-Triazine-based derivatives as potential EGFRWT and EGFRT790M inhibitors: Microwave-assisted synthesis, anticancer evaluation, and molecular docking study. ACS Omega, 7, 7155‒7171. https://doi.org/10.1021%2Facsomega.1c06836
Lin, X., Li, X., & Lin, X. (2020). A review on applications of computational methods in drug screening and design. Molecules, 25(6), 1375. https://doi.org/10.3390/molecules25061375
Lu, C. F., Wang, S. H., Pang, X. J., Zhu, T., Li, H. L., Li, Q. R., ... & Zhang, S. Y. (2020). Synthesis and biological evaluation of amino chalcone derivatives as antiproliferative agents. Molecules, 25(23), 5530. https://doi.org/10.3390/molecules25235530
Marín-Ocampo, L., Veloza, L. A., Abonia, R., & Sepúlveda-Arias, J. C. (2019). Anti-inflammatory activity of triazine derivatives: A systematic review. European Journal of Medicinal Chemistry, 162, 435‒447. https://doi.org/10.1016/j.ejmech.2018.11.027
Mokhtar, A. M., El-Messery, S. M., Ghaly, M. A., & Hassan, G. S. (2020). Targeting EGFR tyrosine kinase: Synthesis, in vitro antitumor evaluation, and molecular modeling studies of benzothiazole-based derivatives. Bioorganic chemistry, 104, 104259. https://doi.org/10.1016/j.bioorg.2020.104259
Patel, R. V., Kumari, P., Rajani, D. P., Pannecouque, C., De Clercq, E., & Chikhalia, K. H. (2012). Antimicrobial, anti-TB, anticancer and anti-HIV evaluation of new s-triazine-based heterocycles. Future Medicinal Chemistry, 4(9), 1053‒1065. https://doi.org/10.4155/fmc.12.57v
Shah, D.R., Modh, R.P., & Chikhalia, K.H. (2014). Privileged s-triazines: structure and pharmacological applications”, Future Medicinal Chemistry, 6(4), 463‒477. https://doi.org/10.4155/fmc.13.212
Sharma, A., Ghabbour, H., Khan, S.T., de la Torre, B.G., Albericio, F., & El-Faham, A. (2017). Novel pyrazolyl-s-triazine derivatives, molecular structure and antimicrobial activity. Journal of Molecular Structure, 1145, 244‒253. https://doi.org/10.1016/j.molstruc.2017.05.040
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209‒249. https://doi.org/10.3322/caac.21660
Syahputra, G., Ambarsari, L., & Sumaryada, T. (2014). Simulasi docking kurkumin enol, bisdemetoksikurkumin dan analognya sebagai inhibitor enzim12-lipoksigenase. Jurnal Biofisika, 10(1), 55‒67.
Zacharie, B., Abbott, S. D., Duceppe, J. S., Gagnon, L., Grouix, B., Geerts, L., Gervais, L., Sarra-Bournet, F., Perron, V., Wilb, N., Penney, C. L., & Laurin, P. (2018). Design and synthesis of new 1,3,5-trisubstituted triazines for the treatment of cancer and inflammation. Chem PubSoc Europe. https://doi.org/10.1002%2Fopen.201800136
